Navigation Links
Umbilical cord blood-derived stem cells studied for lupus therapy
Date:4/11/2011

Tampa, Fla. (April 11, 2011) Human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have been found to offer benefits for treating lupus nephritis (LN) when transplanted into mouse models of systemic lupus erythematosus (SLE). SLE is an autoimmune disease with "myriad immune system aberrations" characterized by diverse clinical conditions, including LN, a leading cause of morbidity and mortality for patients with SLE.

The beneficial results were reported in a study by Taiwanese researchers published in the current issue of Cell Transplantation (20:2), freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

According to corresponding author Dr. Oscar K. Lee of the National Yang-Ming University School of Medicine, MSCs have been shown to possess immune-modulatory capabilities and can alleviate immune responses by inhibiting inflammation as well as the function of mature and immature immune system T cells. Seeking to explore the therapeutic effects of uMSCs in treating LN, their study transplanted umbilical cord blood-derived stem cells into mice modeled with systemic immune diseases closely resembling SLE in humans.

"We found that uMSC transplantation markedly delayed the deterioration of renal function, reduced certain antibody levels, alleviated changes in renal pathology and the development of proteinuria - the presence of excess protein serum in the urine and a sign of renal damage," said Dr. Lee.

The positive difference in survival rate for mice treated at two months of age compared with mice treated at six months of age, led the researchers to conclude that early uMSC transplantation may be most efficacious. The researchers also deduced that their findings favored the use of allogenic (other-donated) rather than autologous (self-donated) MSCs for SLE treatment, which would make sense with an autoimmune disorder.

"The therapeutic effects demonstrated in this pre-clinical study support further exploration of the possibility of using uMSCs from mismatched donors in LN treatment," concluded Dr. Lee.

"The ability of uMSCs to reduce inflammation means that they are likely to be of use in the treatment of autoimmune disorders and this study supports that reasoning and, in this case, also advocates the use of non-self cells," said Dr. David Eve, associate editor of "CELL TRANSPLANTATION" and an instructor at the University of South Florida Center of Excellence for Aging and Brain Repair.


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Human umbilical cord blood cells aid diabetic wound healing
2. Do we clamp the umbilical cord too soon?
3. Specific blood-derived cells promote survival in heart attack model
4. Cord blood-derived CD133+ cells improve cardiac function after myocardial infarction
5. Blueberries may inhibit development of fat cells
6. Outsmarting cancer cells: SLU scientists learn how they spread
7. Dopamine controls formation of new brain cells
8. Mussel adhesive inspires tough coating for living cells
9. Human taste cells regenerate in a dish
10. Discovery of protein that alters nutrition of breast cancer cells
11. Algae that live inside the cells of salamanders are the first known vertebrate endosymbionts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
Breaking Biology Technology: